Jubiliant Life Sciences: Q1FY18 result

Jubiliant Life Sciences Ltd. reported its results for the quarter ended June 30, 2017 today.

The company's total sales for Q1FY18 came in at Rs 1556.3 crore, which represents a 2.62 per cent sequential decline and 9.63 per cent YoY increase. 

The company's pharmaceuticals revenue (contributing 51% to the revenues) was up by 8 per cent YoY and life science ingredients revenue (contributing 46% to the revenues) was up by 13 per cent YoY.

Its operating profit (EBIT) for the quarter amounted to Rs 265.13 crore and its EBIT margin stood at 17.04 per cent.

The company reported PAT of Rs 143.71 crore, which represents a sequential QoQ decline of 3.57 per cent and a YoY decline of 12.33 per cent.

Its finance cost during the quarter declined by 17 per cent YoY to Rs 69 crore.
 
Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients and drug discovery solutions. The pharmaceuticals segment, through its wholly-owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of APIs, solid dosage formulations, radio pharmaceuticals, allergy therapy products and contract manufacturing of sterile and non-sterile products.